48.1 Palpable Breast Mass, Mastitis & Nipple Discharge

ABFM Family Medicine Certification Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Blueprint & Clinical Decision-Making

1.1 Exam Blueprint, FMCLA vs. One-Day Exam & Board Scoring 1.2 Clinical Reasoning, Test-Taking Strategy & Ambiguity Management 1.3 Evidence-Based Medicine & Clinical Practice Guidelines in Primary Care

2 Chapter 2: Healthcare Systems, Practice Management & Quality

2.1 Practice Management, Billing, Coding & Documentation 2.2 Quality Improvement, Patient Safety & Diagnostic Stewardship 2.3 Interprofessional Team-Based Care & Care Coordination

3 Chapter 3: Ethics, Law, Biostatistics & Health Equity

3.1 Medical Ethics, Informed Consent & Surrogate Decision-Making 3.2 Biostatistics, Clinical Epidemiology & Diagnostic Test Interpretation 3.3 Social Determinants of Health, Health Equity & Cultural Humility 3.4 Physician Wellness, Burnout Prevention & Professionalism

4 Chapter 4: Lifestyle Counseling & Behavior Change

4.1 Alcohol Use Screening & Brief Intervention 4.2 Illicit Drug & Cannabis Counseling 4.3 Tobacco & Vaping Cessation Counseling

5 Chapter 5: Nutrition, Physical Activity & Chronic Disease Prevention

5.1 Dietary Counseling for Obesity & Chronic Disease Prevention 5.2 Exercise Prescription & Physical Activity Counseling 5.3 Genetic Risk Assessment & Family History Counseling

6 Chapter 6: Routine Adult Immunizations

6.1 ACIP Adult Respiratory Vaccines: Influenza, COVID-19, RSV & Pneumococcal 6.2 ACIP Adult Non-Respiratory Vaccines: Tdap, Shingrix, HPV & Hep B 6.3 Immunizations in Special Populations: Pregnancy, Asplenia & Immunocompromise

7 Chapter 7: Pediatric Health Maintenance & Surveillance

7.1 Newborn Examination & Early Postnatal Care 7.2 Well-Child Care, Developmental Surveillance & Milestones 7.3 Pediatric & Adolescent Screening: Vision, Hearing, Anemia & Lead 7.4 Pediatric Oral Health, Dental Screening & Fluoride

8 Chapter 8: Behavioral Health & Safety Screening

8.1 Primary Care Depression, Anxiety & Behavioral Health Screening 8.2 Domestic Violence, Intimate Partner Violence & Firearm Safety 8.3 Occupational Health & Recreational Safety Counseling

9 Chapter 9: Adult Preventive Screening: Cardiovascular & Metabolic

9.1 Cardiovascular Disease & Hypertension Screening 9.2 Type 2 Diabetes Screening & Prediabetes Risk Stratification 9.3 Abdominal Aortic Aneurysm & Osteoporosis Screening

10 Chapter 10: Adult Cancer Screening: Breast & Gynecologic

10.1 Breast Cancer Screening & Risk-Assessment 10.2 Cervical Cancer Screening & ASCCP Algorithms 10.3 Skin Cancer Clinical Assessment & Counseling

11 Chapter 11: Adult Cancer Screening: Colorectal, Lung & Prostate

11.1 Colorectal Cancer Screening Modalities & Intervals 11.2 Lung Cancer Screening with Low-Dose CT 11.3 Prostate Cancer Screening & Shared Decision-Making

12 Chapter 12: Sexual Health, Infectious Disease Screening & Contraception

12.1 Sexual Health Counseling & Risk-Reduction Strategies 12.2 STI Screening: Chlamydia, Gonorrhea, Syphilis & Trichomoniasis 12.3 Bloodborne Infectious Disease Screening: HIV & Hepatitis C

13 Chapter 13: Reproductive Life Planning, Lactation & Preoperative Care

13.1 Preconception Planning & Comprehensive Contraception Management 13.2 Lactation Support & Breastfeeding Counseling 13.3 Preoperative Medical Evaluation & Pre-Participation Sports Exam

14 Chapter 14: Emergent Cardiovascular Conditions

14.1 Acute Coronary Syndromes & Myocardial Infarction 14.2 Acute Chest Pain Risk Stratification & Triage 14.3 Acute or Critical Valvular Heart Emergencies

15 Chapter 15: Cardiac Arrhythmias, Heart Failure & Hypertensive Crises

15.1 Acute Atrial & Ventricular Arrhythmias 15.2 Acute Decompensated Heart Failure & Cardiogenic Shock 15.3 Hypertensive Emergency & Urgency Management

16 Chapter 16: Vascular & Thromboembolic Emergencies

16.1 Pulmonary Embolism & Deep Vein Thrombosis 16.2 Acute Aortic Syndromes & Peripheral Vascular Emergencies 16.3 Critical Limb Ischemia & Acute Arterial Occlusion

17 Chapter 17: Neurologic Emergencies: Stroke & Altered Consciousness

17.1 Acute Ischemic Stroke & Intracranial Hemorrhage 17.2 Syncope Evaluation & Status Epilepticus 17.3 Acute Delirium, Encephalopathy & Severe Confusion

18 Chapter 18: Neurologic Trauma & Acute Cranial Emergencies

18.1 Concussion, Moderate-to-Severe TBI & Intracranial Injury 18.2 Thunderclap & Acute Severe Secondary Headaches 18.3 Acute Ophthalmologic Emergencies

19 Chapter 19: Acute Abdominal, Pelvic & Gastrointestinal Emergencies

19.1 Acute Abdominal & Pelvic Pain Triage 19.2 Upper & Lower Gastrointestinal Bleeding 19.3 Acute Hepatic Failure, Cholangitis & Severe Jaundice

20 Chapter 20: Acute Pulmonary & Airway Emergencies

20.1 Acute Hypoxic Respiratory Failure & ARDS 20.2 Severe Community-Acquired Pneumonia & Empyema 20.3 Acute Severe Epistaxis & Airway Obstruction

21 Chapter 21: Acute Traumatic Injuries & Wound Care

21.1 Major Trauma Resuscitation & Initial Assessment 21.2 Burn Assessment, Inhalation Injury & Resuscitation 21.3 Laceration Management, Complex Wounds & Animal Bites

22 Chapter 22: Acute Orthopedic & Musculoskeletal Emergencies

22.1 Acute Ambulatory Fractures & Initial Splinting 22.2 Compartment Syndrome & Major Orthopedic Trauma 22.3 Septic Arthritis & Acute Microcrystalline Crises

23 Chapter 23: Severe Infections, Sepsis & Systemic Emergencies

23.1 Sepsis, Septic Shock & Initial Fluid Resuscitation 23.2 Necrotizing Soft Tissue Infections & Severe CNS Infections 23.3 Anaphylaxis Diagnosis, Epinephrine Dosing & Airway Protection

24 Chapter 24: Metabolic, Endocrine & Electrolyte Emergencies

24.1 Diabetic Ketoacidosis & Hyperosmolar Hyperglycemic State 24.2 Critical Electrolyte Emergencies: Dyskalemias & Dysnatremias 24.3 Severe Calcium Abnormalities & Acute Adrenal Crisis

25 Chapter 25: Hematologic, Urologic & Dental Emergencies

25.1 Severe Symptomatic Anemias & Coagulopathic Emergencies 25.2 Testicular Torsion, Priapism & Acute Urinary Retention 25.3 Urgent Odontogenic Infections & Dental Trauma

26 Chapter 26: Psychiatric, Behavioral & Obstetric/Gynecologic Emergencies

26.1 Suicidal Ideation, Acute Agitation & Behavioral Emergencies 26.2 Acute Physical & Sexual Assault Care 26.3 Life-Threatening Vaginal Bleeding & Ectopic Pregnancy 26.4 Environmental Heat Stroke & Severe Hypothermia

27 Chapter 27: Acute Head, Neck & Neurologic Symptoms

27.1 Primary Acute Headaches: Migraine, Tension & Cluster 27.2 Concussion & Minor Closed Head Injury Evaluation 27.3 Transient Ischemic Attack Evaluation & ABCD2 Risk Scoring

28 Chapter 28: Acute Cranial Nerves, Hearing & Sensory Symptoms

28.1 Peripheral Neuropathies: Bell's Palsy, Carpal Tunnel & Radiculopathy 28.2 Acute Tinnitus, Sudden Sensorineural Hearing Loss & Cerumen Impaction 28.3 Acute Dizziness, Benign Paroxysmal Positional Vertigo & Vestibular Neuritis

29 Chapter 29: Acute Upper Respiratory Tract Infections

29.1 Acute Viral Rhinosinusitis vs. Bacterial Rhinosinusitis 29.2 Acute Pharyngitis: Group A Streptococcus & Centor Criteria 29.3 Acute Otitis Media, Otitis Externa & Serous Effusion

30 Chapter 30: Acute Lower Respiratory Infections & Cough

30.1 Influenza, COVID-19 & Viral Respiratory Syndromes 30.2 Acute Bronchitis & Lower Respiratory Tract Infections 30.3 Ambulatory Community-Acquired Pneumonia

31 Chapter 31: Allergic, Nasal & Non-Infectious Pulmonary Conditions

31.1 Allergic Rhinitis & Acute Non-Anaphylactic Allergic Reactions 31.2 Acute Dyspnea in Ambulatory Care 31.3 Interstitial Lung Diseases & Sarcoidosis Presentation

32 Chapter 32: Acute Chest, Cardiac & Vascular Symptoms

32.1 Palpitations Evaluation & Arrhythmia Triage in Primary Care 32.2 Deep Vein Thrombosis & Superficial Thrombophlebitis 32.3 Ambulatory Hypotension & Orthostasis Evaluation

33 Chapter 33: Acute Upper Gastrointestinal Conditions

33.1 Peptic Ulcer Disease & Gastritis 33.2 Dysphagia, Esophagitis & Acute Esophageal Disorders 33.3 Acute Nausea, Vomiting & Foodborne Illness

34 Chapter 34: Acute Lower Gastrointestinal Conditions

34.1 Acute Infectious Diarrhea & Gastroenteritis 34.2 Acute Constipation & Functional Bowel Changes 34.3 Ano-Rectal Disorders: Hemorrhoids, Fissures, Abscesses & Pruritus Ani

35 Chapter 35: Inflammatory, Functional & Malabsorptive GI Disorders

35.1 Acute Flares of Inflammatory Bowel Disease 35.2 Irritable Bowel Syndrome: Diagnosis, Subtyping & Management 35.3 Celiac Disease & Malabsorption Syndromes

36 Chapter 36: Acute Abdominal, Hepatic & Biliary Disorders

36.1 Ambulatory Abdominal & Pelvic Pain Triage 36.2 Acute Cholecystitis, Biliary Colic & Pancreatitis 36.3 Acute Liver Injury & Viral Hepatitis

37 Chapter 37: Acute Abdominal Wall, Hernias & Dental Conditions

37.1 Abdominal Wall, Inguinal & Ventral Hernias 37.2 Acute Dental Pain, Odontogenic Abscess & Aphthous Ulcers 37.3 Acute Edema: Unilateral vs. Bilateral Diagnostic Evaluation

38 Chapter 38: Acute Infectious Dermatoses

38.1 Bacterial Skin Infections: Impetigo, Cellulitis & Cutaneous Abscesses 38.2 Fungal Skin Infections: Tinea Corporis, Cruris, Pedis & Onychomycosis 38.3 Viral Cutaneous Infections: Herpes Simplex, Zoster & Molluscum Contagiosum

39 Chapter 39: Inflammatory, Allergic & Autoimmune Dermatoses

39.1 Atopic Dermatitis, Contact Dermatitis & Eczematous Flares 39.2 Non-Infectious Rashes: Urticaria, Drug Eruptions & Erythema Multiforme 39.3 Cutaneous Malignancies & Premalignant Lesions: AK, BCC, SCC & Melanoma

40 Chapter 40: Acute Shoulder, Elbow & Upper Extremity Injuries

40.1 Rotator Cuff Pathology, Tendinopathy & Shoulder Impingement 40.2 Lateral & Medial Epicondylitis, Olecranon Bursitis & Elbow Sprains 40.3 Wrist & Hand Soft-Tissue Injuries: De Quervain, TFCC & Finger Sprains

41 Chapter 41: Acute Knee, Ankle & Lower Extremity Injuries

41.1 Meniscal Tears, Ligamentous Knee Injuries & Patellofemoral Pain 41.2 Ankle Sprains, Ottawa Ankle Rules & Achilles Tendinopathy 41.3 Plantar Fasciitis, Shin Splints & Overuse Syndromes

42 Chapter 42: Acute Ambulatory Fractures & Dislocations

42.1 Distal Radius, Scaphoid & Common Upper Extremity Fractures 42.2 Metatarsal, Clavicle & Common Lower Extremity Fractures 42.3 Joint Dislocation Management: Nursemaid's Elbow & Shoulder Subluxation

43 Chapter 43: Acute Axial Musculoskeletal Pain & Falls

43.1 Acute Low Back Pain: Red Flags, Strain & Disc Herniation 43.2 Acute Cervical Strain, Whiplash & Axial Neck Pain 43.3 Evaluation of Falls in Ambulatory & Older Patients

44 Chapter 44: Acute Inflammatory Arthropathies & Generalized Pain

44.1 Acute Inflammatory Arthritis & Spondyloarthropathies 44.2 Myalgias, Rhabdomyolysis & Post-Viral Pain Syndromes 44.3 Acute Non-Headache Pain Management Strategies

45 Chapter 45: Acute Renal, Urinary & Genitourinary Conditions

45.1 Uncomplicated UTI, Pyelonephritis & Acute Urethritis 45.2 Hematuria Workup & Glomerulonephritis 45.3 Nephrolithiasis & Acute Urinary Tract Obstruction

46 Chapter 46: Acute Male Genitourinary & Prostatic Conditions

46.1 Acute Prostatitis, Epididymitis & Orchitis 46.2 Acute Scrotal Pain: Torsion vs Appendage, BPH & Male Genital Emergencies 46.3 Acute Urinary Retention & Incontinence Evaluation

47 Chapter 47: Acute Women's Health & Early Pregnancy Care

47.1 Early Pregnancy Diagnosis, Dating & Initial Complications 47.2 Abnormal Uterine Bleeding & Acute Menstrual Disorders 47.3 Premenstrual Syndrome & Premenstrual Dysphoric Disorder

48 Chapter 48: Breast Disorders, STIs & Pediatric Elimination

48.1 Palpable Breast Mass, Mastitis & Nipple Discharge 48.2 Sexually Transmitted Infections: Diagnosis, Staging & CDC Guidelines 48.3 Pediatric Enuresis & Encopresis

49 Chapter 49: Systemic Signs, Metabolic Dysregulation & Miscellaneous Infections

49.1 Acute Fever, Sepsis Screening & FUO in Primary Care 49.2 Acute Hyperglycemia & Symptomatic Hypoglycemia 49.3 Electrolyte Abnormalities: Mild-to-Moderate Disturbances 49.4 Vector-Borne, Tick-Borne & Rickettsial Illnesses

50 Chapter 50: Chronic Cardiovascular Diseases: Hypertension & Ischemia

50.1 Essential Hypertension Management: 2025 AHA/ACC Guideline & JNC Strategies 50.2 Chronic Coronary Artery Disease & Post-MI Secondary Prevention 50.3 Chronic Heart Failure: HFrEF, HFpEF & Quadruple GDMT

51 Chapter 51: Chronic Vascular, Valvular & Dyslipidemic Diseases

51.1 Peripheral Arterial Disease & Claudication 51.2 Chronic Valvular Heart Disease & Murmur Evaluation 51.3 Lipid Disorders & ASCVD Risk-Based Statin Therapy

52 Chapter 52: Chronic Respiratory Diseases: Asthma & COPD

52.1 Chronic Asthma Management: GINA Stepwise SMART Therapy 52.2 Chronic Obstructive Pulmonary Disease: GOLD Recommendations 52.3 Solitary Pulmonary Nodule Evaluation & Fleischner Society Criteria

53 Chapter 53: Chronic Metabolic Diseases: Diabetes Mellitus

53.1 Type 2 Diabetes Management: ADA Pharmacotherapy Algorithms 53.2 Type 1 Diabetes: Basal-Bolus Insulin, CGMs & Diabetic Complications 53.3 Diabetic Microvascular & Macrovascular Disease Surveillance

54 Chapter 54: Obesity, Nutrition & Metabolic Bone Diseases

54.1 Medical & Behavioral Management of Obesity & Incretin Mimetics 54.2 Osteoporosis & Metabolic Bone Disease: DEXA, FRAX & Antiresorptives 54.3 Nutritional Deficiencies: Vitamin D, B12, Iron & Malnutrition

55 Chapter 55: Chronic Endocrine Disorders

55.1 Primary & Subclinical Hypothyroidism, Hyperthyroidism & Nodules 55.2 Adrenal Disorders: Addison's Disease & Cushing's Syndrome 55.3 Hypercalcemia, Hyperparathyroidism & Pituitary Disorders

56 Chapter 56: Chronic Kidney Disease & Venous Disorders

56.1 Chronic Kidney Disease: KDIGO Staging & Renoprotective Therapy 56.2 Chronic Venous Insufficiency, Stasis Dermatitis & Lymphedema 56.3 Chronic Electrolyte & Acid-Base Management in CKD

57 Chapter 57: Chronic Gastrointestinal & Hepatic Diseases

57.1 Gastroesophageal Reflux Disease, Barrett's Esophagus & Dyspepsia 57.2 Chronic Liver Disease: MASLD/NAFLD, Cirrhosis & Portal Hypertension 57.3 Viral Hepatitis B & C: Long-Term Monitoring & DAA Therapy

58 Chapter 58: Colorectal Surveillance & Chronic Pancreaticobiliary Care

58.1 Post-Polypectomy Colorectal Polyp Surveillance Guidelines 58.2 Chronic Pancreatitis & Exocrine Pancreatic Insufficiency 58.3 Chronic Nausea, Gastroparesis & Functional GI Disorders

59 Chapter 59: Chronic Musculoskeletal & Rheumatologic Disorders

59.1 Osteoarthritis: Hip, Knee & Hand Management 59.2 Spinal Conditions: Spinal Stenosis, Spondylolisthesis & Compression Fractures 59.3 Chronic Myopathies & Fibromyalgia Syndrome

60 Chapter 60: Chronic Neurologic & Neurodegenerative Disorders

60.1 Dementia: Alzheimer's, Vascular & Lewy Body Disease 60.2 Parkinson's Disease & Essential Tremor 60.3 Epilepsy: Chronic Antiseizure Medications & Post-Stroke Care

61 Chapter 61: Chronic Peripheral Nerves, Pain & Sensory Disorders

61.1 Diabetic & Chronic Peripheral Neuropathies 61.2 Chronic Pain Syndromes & Chronic Daily Headaches 61.3 Chronic Tinnitus, Presbycusis & Persistent Dizziness

62 Chapter 62: Chronic Psychiatric Disorders

62.1 Major Depressive Disorder & Generalized Anxiety Disorder 62.2 Bipolar Disorder: Maintenance Pharmacotherapy & Lithium Monitoring 62.3 Adult & Pediatric Attention-Deficit/Hyperactivity Disorder

63 Chapter 63: Chronic Behavioral Health & Neurodevelopmental Conditions

63.1 Chronic Behavioral Conditions: PTSD, OCD & Somatization 63.2 Autism Spectrum Disorder & Intellectual Disabilities 63.3 Eating Disorders: Anorexia Nervosa, Bulimia & Binge Eating

64 Chapter 64: Chronic Substance Use Disorders & Tobacco Cessation

64.1 Alcohol Use Disorder: Pharmacotherapy & Relapse Prevention 64.2 Opioid & Stimulant Use Disorders: MOUD & Harm Reduction 64.3 Longitudinal Tobacco Cessation Pharmacotherapy

65 Chapter 65: Chronic Dermatologic Conditions

65.1 Acne Vulgaris, Rosacea & Seborrheic Dermatitis 65.2 Chronic Plaque Psoriasis & Biologic Therapies 65.3 Chronic Eczema, Hidradenitis Suppurativa & Cutaneous Lupus

66 Chapter 66: Chronic Reproductive, Infectious & Geriatric Special Care

66.1 Chronic Menstrual Disorders, Infertility & Sexual Dysfunction 66.2 Menopause Management & Hormone Replacement Therapy 66.3 Chronic HIV Infection Management & Primary Care Integration 66.4 Gender-Affirming Primary Care & Hormone Therapy 66.5 Advance Care Planning, Palliative Care & End-of-Life Symptom Control

67 Chapter 67: Continuity Care: Sleep, Fatigue, Cancer, Pregnancy & the Adult Preventive Visit

67.1 Chronic Insomnia & Obstructive Sleep Apnea 67.2 Chronic Malaise, Fatigue & ME/CFS 67.3 Primary Care During Cancer Treatment & Survivorship 67.4 Routine Prenatal Care & Longitudinal Pregnancy Management 67.5 The Periodic Adult Health Examination & Medicare Annual Wellness Visit

48.1 Palpable Breast Mass, Mastitis & Nipple Discharge

Key Takeaways Explain This Topic AI

Diagnostic evaluation of a palpable breast mass is strictly age-stratified: women aged <30 years receive targeted breast ultrasound as the initial imaging modality of choice, whereas women aged >=30 years require diagnostic mammography AND targeted ultrasound.

The definitive 'Triple Assessment' for any palpable breast mass comprises clinical breast examination, diagnostic imaging (mammography/ultrasound), and core needle biopsy (CNB); CNB is the gold standard because it preserves architectural histology, differentiates ductal carcinoma in situ (DCIS) from invasive ductal carcinoma (IDC), and allows receptor testing (ER/PR/HER2).

Pathologic nipple discharge is characteristically unilateral, spontaneous, uniductal, and bloody or serosanguinous; the single most common etiology is a benign solitary intraductal papilloma (~40-50%), followed by DCIS or invasive carcinoma (~10-15%), mandating diagnostic mammography, subareolar ultrasound, and terminal duct excision.

Puerperal mastitis is an acute breast cellulitis predominantly caused by Staphylococcus aureus; first-line therapy is oral dicloxacillin or cephalexin (500 mg QID for 10-14 days), and mothers must be strongly counseled to CONTINUE frequent breastfeeding or pumping to relieve milk stasis and prevent breast abscess.

Inflammatory breast cancer is a lethal, rapidly progressive carcinoma presenting with breast erythema, warmth, and 'peau d'orange' edema mimicking acute mastitis; failure to respond to 7-10 days of antibiotics mandates immediate diagnostic imaging and a full-thickness skin punch biopsy to identify neoplastic tumor emboli plugging dermal lymphatics.

Last updated: September 2026

Diagnostic Approach to a Palpable Breast Mass

A palpable breast mass is one of the most common and anxiety-provoking chief complaints encountered in family medicine. While the vast majority (>80% to 90%) of palpable breast masses in premenopausal women represent benign pathology (such as fibrocystic changes, fibroadenomas, or simple cysts), the primary clinical objective is the rapid, definitive exclusion of invasive breast malignancy. Every palpable dominant mass demands systematic diagnostic evaluation regardless of recent normal screening mammography results.

The Age-Stratified Imaging Algorithm

Breast tissue composition changes substantially across the female lifespan. Young women possess dense fibrous and glandular connective tissue, whereas postmenopausal women undergo gradual involution where radiodense parenchyma is replaced by radiolucent adipose tissue. Consequently, the initial imaging modality of choice is strictly stratified by patient age: AGE-STRATIFIED IMAGING FOR A PALPABLE BREAST MASS

• Patient Age Category Initial Imaging Modality Clinical Rationale
• ═══════════════════════════════════════════════════════════════════════════════════════════════
• Women Aged < 30 Years Targeted Breast Ultrasound Dense fibroglandular tissue produces
• (Initial Diagnostic Modality) mammographic obscuration (false negatives);
• ultrasound differentiates cystic from

solid masses with exceptional sensitivity.

• Women Aged >= 30 Years Diagnostic Mammography Bilateral diagnostic mammogram (spot
• PLUS Targeted Breast Ultrasound compression/magnification) assesses micro-
• (Combined Modality) calcifications, architectural distortion, and
• occult multifocal disease; ultrasound

characterizes the palpable focal index lesion.

• ═══════════════════════════════════════════════════════════════════════════════════════════════
• 1. Women Aged < 30 Years (Targeted Ultrasound First)

In women younger than 30 years (and pregnant or lactating women of any age), ionizing radiation should be minimized, and dense breast tissue renders conventional mammography insensitive.

Targeted Breast Ultrasound is the initial diagnostic test of choice. It immediately answers the critical clinical question: Is the palpable mass cystic or solid?

Simple Cyst : Demonstrates anechoic lumen, smooth thin margins, round or oval shape, and posterior acoustic enhancement with no internal vascularity or wall nodularity. Simple cysts are entirely benign (BI-RADS 2). Management is reassurance; therapeutic aspiration is indicated only if the cyst is painful, tensely distended, or symptomatic.

Complicated Cyst : Contains low-level internal echoes or fluid-debris levels without thick walls or vascularity (BI-RADS 3). Follow with repeat ultrasound in 6 months or perform fine-needle evacuation.

Complex Solid-Cystic or Solid Mass : Displays internal hypoechoic solid tissue, thick irregular septations, or vascularity. This requires diagnostic bilateral mammography followed by image-guided Core Needle Biopsy (CNB) .

2. Women Aged >= 30 Years (Diagnostic Mammogram + Targeted Ultrasound)

In women aged 30 and older, initial evaluation requires a Diagnostic Mammogram accompanied by Targeted Breast Ultrasound .

Diagnostic vs. Screening Mammography :

A screening mammogram is a standard 2-view study (craniocaudal [CC] and mediolateral oblique [MLO]) performed on asymptomatic individuals.

A diagnostic mammogram is an individualized, problem-focused study performed with an on-site radiologist. It includes specialized views: spot compression (displaces overlapping glandular parenchyma to verify a true lesion) and magnification views (evaluates pleomorphic microcalcifications and fine spiculation).

Mammography evaluates both breasts to detect non-palpable multicentric or contralateral synchronous lesions.

Targeted ultrasound is simultaneously performed over the palpable abnormality to determine internal echo texture and margins.

The "Triple Assessment" & The Superiority of Core Needle Biopsy

The diagnostic safety net for breast lump evaluation is the internationally validated Triple Assessment . When all three components are concordant, the diagnostic accuracy exceeds 99%.

The Three Components of the Triple Assessment

Clinical Breast Examination (CBE) : Precise localization, size measurement, mobility, skin dimpling, nipple retraction, chest wall fixation, and regional lymph node staging (axillary, supraclavicular, infraclavicular).

Diagnostic Breast Imaging : Age-appropriate imaging (diagnostic mammography and/or targeted ultrasound) culminating in a standardized Breast Imaging Reporting and Data System (BI-RADS) category.

Tissue Histopathology : Percutaneous image-guided tissue sampling. THE TRIPLE ASSESSMENT CONCORDANCE MATRIX

• Component Benign Profile Malignant Profile
• ═════════════════════════════════════════════════════════════════════════════════════════════
• Clinical Exam Smooth, soft/rubbery, mobile, Hard, irregular margins, fixed,
• non-tender, no skin tethering skin dimpling, nipple retraction

• Diagnostic Imaging Circumscribed oval mass, Spiculated, taller-than-wide, micro-
• (Mammogram / Ultrasound) anechoic cyst, BI-RADS 2 or 3 calcifications, shadowing, BI-RADS 4/5

• Tissue Biopsy Fibroadenoma, fibrocystic tissue, Invasive ductal carcinoma, DCIS,
• (Core Needle Biopsy) stromal fibrosis invasive lobular carcinoma
• ═════════════════════════════════════════════════════════════════════════════════════════════
• RULE OF DISCORDANCE: If ANY ONE of the three components is suspicious or discordant with

the others, surgical excision or re-biopsy is MANDATORY to rule out occult carcinoma.

Why Core Needle Biopsy (CNB) is the Gold Standard over FNA

Historically, Fine Needle Aspiration (FNA) was widely used for breast lumps. Today, image-guided (ultrasound- or stereotactic-guided) Core Needle Biopsy (CNB) is the unquestioned standard of care. Family physicians must recognize why FNA is no longer sufficient for suspicious solid lesions:

Tissue Architecture Preservation : CNB extracts intact cores of tissue (using a 14-gauge spring-loaded cutting needle), preserving the histologic relationship between epithelial cells, the basement membrane, and the surrounding stroma.

Differentiating DCIS from Invasive Carcinoma :

FNA provides only single-cell cytologic smears without architecture. Cytology can confirm the presence of malignant epithelial cells, but FNA CANNOT determine whether tumor cells have broken through the basement membrane .

CNB directly visualizes the basement membrane, decisively distinguishing non-invasive Ductal Carcinoma In Situ (DCIS) from Invasive Ductal Carcinoma (IDC) . This distinction fundamentally alters surgical staging (e.g., determining the necessity of sentinel lymph node biopsy).

Biomarker and Receptor Profiling : CNB supplies sufficient tissue volume to perform immunohistochemical staining and fluorescence in situ hybridization (FISH) for therapeutic biomarkers: Estrogen Receptor (ER) , Progesterone Receptor (PR) , Human Epidermal Growth Factor Receptor 2 (HER2/neu) , and Ki-67 proliferation index. Neoadjuvant chemotherapy and endocrine therapy decisions depend completely on these receptors.

Low Non-Diagnostic Rate : CNB has an insufficient sampling rate of <2%, compared to up to 15% to 20% for FNA.

• Common Benign Breast Masses
• 1. Fibroadenoma

Epidemiology : The most common solid benign breast neoplasm in adolescent girls and young women (peak incidence between ages 15 and 35 years ).

Pathophysiology : A benign fibroepithelial proliferation arising from the terminal duct lobular unit (TDLU). The stromal component responds to circulating ovarian sex hormones.

Clinical Presentation : A solitary, well-circumscribed, firm, rubbery, smoothly bordered, non-tender, highly mobile ("breast mouse") mass. Size typically ranges from 1 to 3 cm. The mass frequently enlarges during periods of estrogen stimulation (pregnancy, menses, oral contraceptive initiation) and undergoes hyalinization, calcification, and involution after menopause.

Imaging Characteristics : Ultrasound demonstrates an oval, circumscribed, hypoechoic or isoechoic mass with a horizontal orientation ("wider than tall"), thin echogenic pseudocapsule, and uniform internal echogenicity (BI-RADS 2 or 3).

Clinical Management :

In women <25 years with classic imaging, conservative observation with clinical exam and repeat ultrasound in 6 months is safe.

Core needle biopsy is indicated if the lesion is >=2 to 3 cm, exhibits atypical imaging features, is rapidly enlarging, or if the patient desires definitive confirmation.

Surgical excision is reserved for giant fibroadenomas (>5 cm), persistent pain, or suspicion of a phyllodes tumor.

2. Fibrocystic Changes

Epidemiology : The most common benign condition of the breast overall, affecting up to 50% to 60% of premenopausal women aged 20 to 50 years.

Pathophysiology : An exaggerated physiologic tissue response to cyclical fluctuations of estrogen and progesterone, characterized by glandular ductal dilation (micro- and macrocysts), stromal fibrosis, and apocrine metaplasia.

Clinical Presentation : Bilateral, diffuse, fluctuating breast nodularity (frequently described as a "cobblestone" or "bag of peas" texture) localized predominantly to the upper outer quadrants. Associated with cyclical premenstrual mastalgia and swelling that characteristically peaks during the late luteal phase (several days before menses) and dramatically regresses following menstrual onset.

Clinical Management :

Reassurance that fibrocystic changes without atypia do not confer increased risk of breast carcinoma.

Supportive mechanical measures: well-fitting, supportive brassiere (including sports bras during exercise).

Lifestyle and medical measures: scheduled NSAIDs (oral ibuprofen or naproxen; topical diclofenac gel), reduction of dietary caffeine and sodium (which may reduce fluid retention), and evening primrose oil. In severe refractory cases, low-dose oral contraceptives or danazol may be considered.

3. Intraductal Papilloma

Pathophysiology : A benign, localized fibroepithelial polypoid arborization growing within the lumen of a major subareolar lactiferous duct.

Clinical Significance : The single most common cause of pathologic nipple discharge (accounting for 40% to 50% of cases).

Clinical Presentation : Typically presents with spontaneous, unilateral, uniductal serosanguinous or frankly bloody nipple discharge in premenopausal or perimenopausal women (ages 30-50). Because the polyp is usually microscopic (<2 to 5 mm) and hidden directly beneath the nipple-areolar complex, a palpable mass is absent in >80% of cases.

Diagnostic Workup & Management : Diagnostic mammogram and targeted retroareolar high-resolution ultrasound. Ductography (galactography) or ductoscopy may reveal a lumen-filling defect. Definitive management requires surgical referral for microdochectomy (selective terminal duct excision) , which provides therapeutic symptom resolution and histological examination to rule out papillary DCIS.

4. Other Benign Mimickers of Carcinoma

Phyllodes Tumor : A rare fibroepithelial neoplasm characterized by hypercellular stroma arranged in leaf-like projections. Occurs predominantly in women aged 40-50. Presents as a rapidly expanding, large (often >4-5 cm), mobile mass. While most are benign, 10% to 25% are malignant with potential for hematogenous pulmonary metastasis. Treatment requires wide local excision with clear histological margins (>=1 cm) ; enucleation leads to rapid local recurrence.

Fat Necrosis : A benign, non-suppurative inflammatory process following blunt breast trauma, seatbelt injury, reduction mammoplasty, biopsy, or radiation therapy. Can produce an irregular, hard, fixed mass with skin retraction, closely mimicking invasive carcinoma clinically and mammographically (lipid cysts, coarse calcifications). Core needle biopsy confirms foamy lipid-laden macrophages, foreign body giant cells, and fat globules.

Mammary Duct Ectasia : Dilatation of subareolar collecting ducts with periductal inflammation and lipid accumulation, typically in perimenopausal or postmenopausal multiparous women. Presents with thick, sticky, green, white, or brown multi-pore nipple discharge, nipple retraction, and a subareolar mass.

Pathologic vs. Physiologic Nipple Discharge

Nipple discharge accounts for approximately 5% to 10% of outpatient breast complaints. Clinicians must immediately categorize nipple discharge as either physiologic (non-pathologic) or pathologic (suspicious) using distinct clinical features. COMPARATIVE MATRIX: NIPPLE DISCHARGE EVALUATION

• Feature Physiologic Discharge (Galactorrhea) Pathologic Nipple Discharge
• ═══════════════════════════════════════════════════════════════════════════════════════════════════
• Laterality Bilateral (both breasts) Unilateral (strictly one breast)

• Spontaneity Non-spontaneous (requires manual Spontaneous (discharges onto clothing/bra
• expression or mechanical stimulation) without any physical touch)

• Ductal Orifices Multiductal (emanates from multiple Uniductal (emanates consistently from a
• duct pores across the nipple) single isolated duct pore)

• Fluid Color / Quality Milky (white), clear, yellow, straw- Bloody (frankly red), serosanguinous
• colored, dark green, or brownish (pink/orange), or clear/watery ("serous")

• Palpable Abnormality No associated discrete breast mass Frequently associated with a discrete
• palpable lump or focal thickening

• Patient Demographics Reproductive-age females; non-pregnant Postmenopausal women or MEN
• or postpartum females (ANY discharge in a male is suspicious)

• Underlying Etiology Endocrine dysfunction (prolactinoma, Intraductal papilloma (~45%), duct ectasia,
• hypothyroidism), medication adverse Ductal Carcinoma In Situ (DCIS ~10-15%),
• effects, chest wall stimulation Invasive Ductal Carcinoma
• ═══════════════════════════════════════════════════════════════════════════════════════════════════
• Workup of Physiologic Nipple Discharge (Galactorrhea)

True galactorrhea is the inappropriate non-puerperal discharge of milky fluid from multiple ducts bilaterally. It is driven by systemic neuroendocrine mechanisms rather than primary breast parenchymal lesions:

Urine or Serum Human Chorionic Gonadotropin (hCG) : Mandatory initial test to exclude occult pregnancy.

Serum Prolactin Level : Drawn in a fasting, non-stressed state (avoid breast exam or sexual intercourse for 24 hours prior, as tactile nipple stimulation triggers prolactin release).

If serum prolactin is significantly elevated (>100 to 200 ng/mL), obtain a Contrast-Enhanced Pituitary MRI to identify a prolactin-secreting pituitary microadenoma (<10 mm) or macroadenoma (>=10 mm).

Serum Thyroid-Stimulating Hormone (TSH) : Primary hypothyroidism causes compensatory elevation of hypothalamic Thyrotropin-Releasing Hormone (TRH). TRH directly stimulates anterior pituitary lactotrophs, producing hyperprolactinemia and galactorrhea. Correcting hypothyroidism with levothyroxine completely resolves the discharge.

Medication History (Dopamine Blockade) : Dopamine is the primary physiologic inhibitor of pituitary prolactin secretion via hypothalamic tuberoinfundibular pathways. Any agent blocking dopamine D2 receptors causes hyperprolactinemia:

Antipsychotics : First-generation neuroleptics (haloperidol, fluphenazine) and second-generation agents (notably risperidone and paliperidone);

• Prokinetic / Antiemetic Agents : Metoclopramide and domperidone;
• Antidepressants : SSRIs, SNRIs, and Tricyclic Antidepressants (TCAs);

Antihypertensives : Methyldopa, verapamil, and reserpine.

Renal Function (BUN / Serum Creatinine) : Chronic kidney disease reduces the clearance of circulating prolactin.

Workup of Pathologic Nipple Discharge

Any discharge meeting pathologic criteria (unilateral, spontaneous, bloody/serosanguinous, uniductal) requires aggressive investigation to rule out malignancy:

Diagnostic Breast Imaging : Diagnostic bilateral mammogram (including retroareolar magnification views) AND targeted high-resolution subareolar ultrasound to identify intraductal lesions, calcifications, or masses.

Surgical Referral : Mandatory referral for surgical duct exploration and terminal duct excision (microdochectomy) . Removing the involved duct system resolves the discharge and provides definitive histologic diagnosis.

Diagnostic Pitfall : Nipple discharge cytology (smearing fluid on a slide) has an unacceptably high false-negative rate (>50%) and should NOT be used to exclude malignancy.

• Infectious & Inflammatory Breast Disorders
• 1. Puerperal (Lactational) Mastitis

Epidemiology : Occurs in approximately 10% to 20% of lactating women, most frequently during the first 6 to 12 weeks postpartum or during abrupt weaning transitions.

Pathophysiology : Milk stasis is the primary initiating event (incomplete emptying, skipped feedings, poor infant latch, or blocked lactiferous ducts). Stagnant milk provides a rich culture medium. Disrupted epithelial integrity from sore, cracked, or traumatized nipples permits retrograde entry of maternal skin flora or infant nasopharyngeal flora.

Microbiology : Staphylococcus aureus (both Methicillin-Sensitive [MSSA] and Methicillin-Resistant [MRSA]) is responsible for >75% of cases. Less common organisms include Streptococcus pyogenes (Group A Strep), Streptococcus agalactiae (Group B Strep), and coagulase-negative staphylococci.

Clinical Presentation : Sudden onset of unilateral focal breast erythema, intense localized tenderness, swelling, induration, accompanied by systemic manifestations: high fever (>38.3°C [101°F]), shaking chills, tachycardia, myalgias, and severe fatigue. ANTIMICROBIAL REGIMENS FOR PUERPERAL MASTITIS

• Clinical Category Preferred Guideline Antibiotic Regimen Dosage & Duration
• ═════════════════════════════════════════════════════════════════════════════════════════════
• Outpatient, MSSA Dicloxacillin 500 mg PO QID x 10-14 days
• (Standard First-Line) OR Cephalexin 500 mg PO QID x 10-14 days

• Penicillin-Allergic Clindamycin 300 mg PO QID x 10-14 days
• (Mild to Severe)

• Suspected MRSA Trimethoprim-Sulfamethoxazole (TMP-SMX)* 1 to 2 DS tablets PO BID x 10-14 days
• OR Failed First-Line OR Clindamycin 300-450 mg PO QID x 10-14 days
• ═════════════════════════════════════════════════════════════════════════════════════════════
• *SAFETY CAUTION: Avoid TMP-SMX in mothers breastfeeding healthy full-term infants younger than

2 months or infants with hyperbilirubinemia / G6PD deficiency due to risk of kernicterus.

Important

CRITICAL CLINICAL PEARL: PRESERVE AND CONTINUE BREASTFEEDING The single most common management error by primary care clinicians is advising an infected mother to cease breastfeeding. Ceasing lactation abruptly dramatically worsens milk stasis, accelerating the development of a frank breast abscess.

Mothers MUST be strongly encouraged to CONTINUE frequent breastfeeding or pumping every 2 to 3 hours. Nursing should begin on the affected breast to ensure complete emptying. Ingesting milk from a mother with mastitis poses NO danger to a healthy infant , as maternal gastric acid and digestive enzymes rapidly neutralize the bacteria. If pain prevents direct latching, the mother must pump the affected breast and nurse from the unaffected side.

2. Breast Abscess

Pathophysiology : A localized collection of purulent exudate within the breast stroma. It arises as a direct complication in 3% to 11% of acute mastitis cases due to delayed antibiotic initiation or incomplete bacterial clearance.

Clinical Signs & Red Flags :

Persistent high fevers, leukocytosis, and systemic toxicity after 48 to 72 hours of appropriate oral antibiotic therapy ;

A distinct, palpable, exquisitely tender, fluctuant mass or area of induration with overlying tense, shiny, erythematous skin.

Diagnostic Confirmation : Urgent Targeted Bedside Breast Ultrasound . Ultrasound readily distinguishes a solid phlegmon (hyperechoic tissue edema) from an abscess cavity, seen as an anechoic or hypoechoic fluid collection with thick, irregular walls, internal debris/septations, and posterior acoustic enhancement.

Management :

Ultrasound-Guided Percutaneous Needle Aspiration : The first-line intervention for abscesses <5 cm. Aspirated pus is sent for Gram stain, culture, and antimicrobial susceptibility. Aspiration is repeated every 2 to 3 days until fluid no longer re-accumulates.

Percutaneous Catheter Drainage : For larger cavities (>=3 to 5 cm) or when serial aspiration fails; a small pigtail catheter is placed for continuous drainage.

Surgical Incision & Drainage (I&D) : Reserved for very large multilocular abscesses, necrotic overlying skin, or failed percutaneous drainage. Surgical drainage carries higher risks of milk fistula formation and cosmetic scarring.

Lactation Guidance : The mother should continue breastfeeding from the contralateral unaffected breast. The affected breast must be regularly pumped and the milk discarded until drainage ceases, after which direct nursing may resume.

3. Inflammatory Breast Cancer (IBC): The Lethal Mimicker

Caution

BOARD EXAM ALERT: INFLAMMATORY BREAST CANCER (IBC) Inflammatory breast cancer is the most aggressive and lethal form of primary breast malignancy (representing 1-2% of all breast cancers but accounting for 10% of breast cancer mortality). It is notorious on board examinations because it presents identically to acute mastitis .

Clinical Presentation :

Rapid onset (typically <3 months) of diffuse erythema, warmth, severe breast enlargement, tenderness, and marked skin edema.

"Peau d'orange" (Orange Peel Skin) : Thickened, dimpled, indurated skin resulting from cutaneous lymphatic obstruction.

Erythema must involve at least one-third (>=33%) of the entire breast skin surface .

A discrete underlying palpable mass is ABSENT in over 50% to 70% of cases because the tumor grows in a diffuse sheet-like permeation pattern.

Ipsilateral axillary and supraclavicular lymphadenopathy is present in up to 75% of patients at initial presentation.

Pathophysiologic Mechanism : Neoplastic tumor emboli invade and plug the superficial dermal lymphatic capillaries , obstructing lymphatic drainage and causing severe interstitial lymphedema and reactive hyperemia.

The Critical Clinical Red Flags :

Any woman presenting with apparent mastitis who is non-lactating or postmenopausal ;

Any lactating woman treated for presumed mastitis who fails to demonstrate rapid clinical improvement within 7 to 10 days of guideline-directed antibiotic therapy.

Definitive Diagnostic Workup :

Immediate Diagnostic Bilateral Mammography and Targeted Ultrasound (demonstrates skin thickening >2 mm, diffuse stromal coarsening, and suspicious regional lymph nodes);

Full-Thickness Skin Punch Biopsy (>=4 mm) : Performed directly over the most indurated, erythematous area of peau d'orange skin. Demonstrating neoplastic carcinoma emboli within the dermal lymphatic channels is pathognomonic and confirms the diagnosis (T4d staging);

Core needle biopsy of any underlying breast parenchymal mass or abnormal axillary lymph nodes.

Loading diagram... Age-Stratified Diagnostic Triage for a Palpable Breast Mass